ArticleAmerican journal of translational research2025
Entecavir provides favorable virological control but minimal metabolic benefit in patients with Chronic Hepatitis B and MAFLD.
Baojian Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.